Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Jordan Chussler

Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal

After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares are surging in the wake of an agreement with GLP-1 maker Novo Nordisk (NYSE: NVO)—the very company that filed a patent infringement lawsuit against Hims & Hers on Feb. 9.

After having to pull its compounded semaglutide modeled after Novo Nordisk’s weight loss drugs, Wegovy and Ozempic, Hims & Hers announced in a press release that the two firms have entered into a strategic partnership, making Novo Nordisk’s obesity drugs available through the telehealth platform. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.